Knight Therapeutics Inc | GUD

Knight Therapeutics Inc traded at 4.44 this Thursday March 30th, increasing 0.02 or 0.45 percent since the previous trading session. Looking back, over the last four weeks, Knight Therapeutics Inc gained 13.11 percent. Over the last 12 months, its price fell by 14.94 percent. Looking ahead, we forecast Knight Therapeutics Inc to be priced at 4.36 by the end of this quarter and at 4.02 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
4.44
Daily Change
0.45%
Yearly
-14.94%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Omeros 4.44 -0.09 -1.99% -26.12%

Indexes Price Day Year
CATSX 19941 103.34 0.52% -8.90%

Knight Therapeutics Inc
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company is engaged in the development, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It also finances other life sciences companies, invests in venture capital funds and develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company’s products include EXELON, BIJUVA, IMVEXXY, IBSRELA, TRELSTAR Prostate, TRELSTAR Endometriosis, Nerlynx, Nerlynx Patient Checklist, Nerlynx Prescriber Checklist, Burinex, Probuphine, Movantik and Neuragen. It owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. The Company’s subsidiary includes Knight Therapeutics International S.A., which develops pharmaceuticals, including those used to treat neglected tropical diseases and rare pediatric diseases.